Floatz logo

DEXAMETHASONE

Relapsed or Refractory Solid Tumors

Fox Chase Cancer CenterSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Relapsed or Refractory Solid Tumors cohort.

Asset / SponsorPhaseRating
LENVATINIB
Merck Sharp & Dohme LLC
Phase 2B
Epirubicin
Fox Chase Cancer Center
Phase 1/2CCC
Cyclophosphamide
Fox Chase Cancer Center
Phase 1/2CCC
Pembrolizumab
Fox Chase Cancer Center
Phase 1/2CCC
cc-5013
Fox Chase Cancer Center
Phase 1/2CCC
Brontictuzumab
OncoMed Pharmaceuticals, Inc.
Phase 1CC

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →